News
Media
Puzzler
Publications
CME/CE
Resources
Conferences
Partnerships
Subscribe
Editorial

|Articles|April 6, 2015

Test article for multiple authors

Test article for many authors and maintaining author order.

Bennett, Lowry, Newman.

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Related Content

ALYFTREK phase 3 data support pediatric CFTR modulator submissions | Image Credit: © Feng - stock.adobe.com.

ALYFTREK phase 3 data support pediatric CFTR modulator submissions

ByMorgan Ebert, Executive Editor

June 8th 2026

Earlier egg introduction guidelines linked to measurable decline in infant egg allergy prevalence | Image Credit: © LIGHTFIELD STUDIOS - stock.adobe.com.

Earlier egg introduction guidelines linked to measurable decline in infant egg allergy prevalence

ByMorgan Ebert, Executive Editor

June 8th 2026

FDA expands marstacimab approval to children ages 6–11 and hemophilia patients with inhibitors

FDA expands marstacimab (HYMPAVZI) approval to children ages 6–11 and hemophilia patients with inhibitors

ByMorgan Ebert, Executive Editor

June 8th 2026

Pediatric clinical trials update: May 2026 | Image credit: putilov_denis - Adobe Stock

Pediatric clinical trials update: May 2026

ByMorgan Ebert, Executive Editor

June 5th 2026

Simple screening questions may help pediatricians identify hidradenitis suppurativa earlier

Simple screening questions may help pediatricians identify hidradenitis suppurativa earlier

ByColleen Cotton, MD, FAAD

June 5th 2026

Latest CME

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Nihar R. Desai, MD, MPH; Martha Gulati, MD, MS, FACC, FAHA, MASPC, FESC, FSCCT (hon), FRCP Edin

Trending on Contemporary Pediatrics

Earlier egg introduction guidelines linked to measurable decline in infant egg allergy prevalence

Pediatric clinical trials update: May 2026

FDA expands marstacimab (HYMPAVZI) approval to children ages 6–11 and hemophilia patients with inhibitors

ALYFTREK phase 3 data support pediatric CFTR modulator submissions

RSV Diagnosis: Why Specific Testing Matters for RSV Management